Genentech (RHHBY) and Biogen Idec, Inc. (Massachusetts) (BIIB) Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case
7/16/2013 9:49:50 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Copenhagen, Denmark; July 15, 2013 – Genmab A/S (OMX: GEN) announced today that the U.S. Court of Appeals for the Federal Circuit has declined the request for re-hearing. The court upheld its judgment in favor of GlaxoSmithKline (GSK) in the patent infringement case involving Arzerra® brought against GSK by Genentech and Biogen Idec.
Help employers find you! Check out all the jobs and post your resume.
comments powered by